VEEV
Strong BuyPremium GrowerAI pickVeeva Systems Inc. · Healthcare · United States · $52.3B cap · $502.1M/day traded
$310.34 -2.4% · close 29 Oct · scored 30 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on VEEV (Apr 2026), freeReport expected 25 Nov: the next-year EPS estimate has risen 2.2% over the last 14 weeks.
As of 30 Oct 2026, MoatMap's StockRank for Veeva Systems Inc. (VEEV) is 82/100, ranked against 24,000+ stocks in 35 markets (Quality 79, Value 20, Momentum 80, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Veeva Systems is the leading cloud software provider for the life sciences industry, covering clinical trials, regulatory filings, quality, safety and commercial CRM. Its products are embedded in drug makers' regulated workflows, which creates very high switching costs, and it keeps winning share: another top-20 biopharma company recently chose Vault CRM, and it continues to add quality and clinical customers such as Oxford Biomedica. The company holds a large net cash position, funds itself entirely from operating cash flow, is led by its founder, and has started buying back shares (0.87% of shares in 90 days). It is also shipping AI agents such as the Study Builder Agent and the Falcon Router that make its platform more valuable per customer rather than replacing seats. Forward earnings estimates rose 2.2% over about four weeks. In a world where yields stay high, a cash-rich, high-margin compounder with no refinancing needs stands out.
ABOUT VEEVA SYSTEMS INC.
Read
Veeva Systems Inc. is a leading provider of cloud-based software for the global life sciences industry, offering solutions for CRM, content management, clinical trials, and quality management. The company dominates the life sciences cloud software market with a comprehensive suite of purpose-built applications, creating high switching costs for pharmaceutical and biotech companies. Veeva is a critical technology partner for the life sciences industry, driving digital transformation and compliance for drug development and commercialization.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.7B | 3.2B | 14.0% | 3.5B | 3.7B | 4.1B | 13.9% |
| EPS | 3.14 | 3.27 | 4.41 | 5.55 | 20.9% | 6.10 | 6.33 | 7.02 | 12.5% |
| Shares | 158.2M | 161.3M | 162.6M | 163.8M | +3.5% | 161.9M | — | — | — |
| Debt | 61.0M | 55.8M | 75.8M | 95.9M | 16.3% | 151.7M | — | — | — |
| Equity | 3.7B | 4.6B | 5.8B | 7.2B | 24.7% | — | — | — | — |
| Op CF | 780.5M | 911.3M | 1.1B | 1.4B | 21.9% | 1.7B | — | — | — |
| Inv CF | -1.0B | -1.1B | -700.1M | -1.1B | — | — | — | — | — |
| Fin CF | -19.4M | -16.2M | 26.1M | -9.3M | — | — | — | — | — |
Above its 200-day average and 5% below its 52-week high.
Swung more than 52% of stocks we rank over the past year (43% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VEEV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VEEV | Veeva Systems Inc.(you) | $52.3B | 82 | Strong Buy |
| BTSG | BrightSpring Health Services, Inc. | $11.9B | 80 | Strong Buy |
| PME.AX | Pro Medicus Limited | $14.6B | 75 | Buy |
| HQY | HealthEquity, Inc. | $8.6B | 83 | Strong Buy |
| HNGE | Hinge Health, Inc. | $9.0B | 75 | Buy |
| 2413.T | M3, Inc. | $8.1B | 74 | Buy |
| DOCS | Doximity, Inc. | $6.0B | 76 | Buy |
| WAY | Waystar Holding Corp. | $5.5B | 75 | Buy |
| TEM | Tempus AI, Inc. | $12.3B | 41 | Hold |
| IKS.NS | Inventurus Knowledge Solutions Limited | $2.9B | 69 | Buy |
Peer medians: ROE 2.7% · P/E 23.5x · Gross margin 53.5%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.